Skip Nav Destination
Issues
1 January 2008
-
Cover Image
Cover Image
Molecular docking of celastrol with Hsp90 and Hsp90-Cdc37 complex. The chemical structure of celastrol (upper left), ribbon view of the Hsp90-Cdc37 complex (upper right), Hsp90-celastrol binding pocket (middle) and Hsp90-Cdc37-celastrol binding pocket (lower left) are shown. Only amino acid residues close to celastrol are displayed for clarity. Also present is the superimposition of Hsp90-celastrol (brown) complex with the Hsp90-p23/Sba1 (blue) X-ray structure (lower right). The ATP analogue (AMPPNP) is shown and the "lid" segment is colored in yellow for Hsp90-celastrol and pink for Hsp90-p23. For details, see Zhang et al. in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Spotlight on Molecular Profiling
Research Articles: Therapeutics, Targets, and Development
Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel
Tristan M. Sissung; Romano Danesi; Douglas K. Price; Seth M. Steinberg; Ronald de Wit; Muhammad Zahid; Nilesh Gaikwad; Ercole Cavalieri; William L. Dahut; Dan L. Sackett; William D. Figg; Alex Sparreboom
CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells
Linhua Jin; Yoko Tabe; Sergej Konoplev; Yuanyuan Xu; Clinton E. Leysath; Hongbo Lu; Shinya Kimura; Akimichi Ohsaka; Mary-Beth Rios; Leslie Calvert; Hagop Kantarjian; Michael Andreeff; Marina Konopleva
Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of Integrin-linked kinase (ILK)
Lincoln A. Edwards; Janet Woo; Lynsey A. Huxham; Maite Verreault; Wieslawa H. Dragowska; Gigi Chiu; Ashish Rajput; Alastair H. Kyle; Jessica Kalra; Donald Yapp; Hong Yan; Andrew I. Minchinton; David Huntsman; Tim Daynard; Dawn N. Waterhouse; B. Thiessen; Shoukat Dedhar; Marcel B. Bally
Molecular profiling of angiogenesis with targeted ultrasound imaging: early assessment of antiangiogenic therapy effects
Moritz Palmowski; Jochen Huppert; Gesa Ladewig; Peter Hauff; Michael Reinhardt; Margareta M. Mueller; Eva C. Woenne; Juergen W. Jenne; Mathias Maurer; Guenter W. Kauffmann; Wolfhard Semmler; Fabian Kiessling
Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth
Brian Clem; Sucheta Telang; Amy Clem; Abdullah Yalcin; Jason Meier; Alan Simmons; Mary Ann Rasku; Sengodagounder Arumugam; William L. Dean; John Eaton; Andrew Lane; John O. Trent; Jason Chesney
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds